#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Anti-glomerular basement membrane disease Fibrosarcoma metastatic Lupus nephritis Lymphangioma Tuberous sclerosis complex Granulomatosis with polyangiitis Spinal cord injury Langerhans' cell histiocytosis Human papilloma virus immunisation Liposarcoma recurrent Chronic graft versus host disease in liver Hereditary neuropathic amyloidosis Anal squamous cell carcinoma Type IIa hyperlipidaemia Lennox-Gastaut syndrome More trials…

    Learn about Rare Diseases

    Idiopathic pulmonary fibrosis Sarcoma – Basic Information Choroid melanoma Waldenstrom’s macroglobulinaemia SAPHO syndrome – Trials in Disease Pleomorphic leiomyosarcoma – Life with Disease Von Willebrand’s disease Focal segmental glomerulosclerosis – Treatment Gastrointestinal stromal tumour – Basic Information Marginal zone lymphoma refractory – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Nemolizumab Pasireotide Patritumab Deruxtecan Rizolipase PEGVISOMANT Remimazolam Prasugrel Rbd5044 Sodium SONLICROMANOL HYDROCHLORIDE Fluvastatin Zalunfiban Abiraterone Acetate Glucose Azd2693 Sodium Pegipanermin Hu5F9‐G4 Mbs2320 Sodium Hypochlorite Anhydrous Cholestyramine Sodium Laurilsulfate More therapies…

    Learn about Your Condition

    Cervix carcinoma stage I Subarachnoid haemorrhage Hairy cell leukaemia Corticobasal degeneration Myocardial infarction Lung neoplasm malignant Deep vein thrombosis Cardiac sarcoidosis Anal incontinence Anal cancer stage III Ligament sprain Migraine Gastrointestinal carcinoma Psychotic behaviour Anogenital warts More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Groupe Hospitalier du Havre – Hôpital Jacques…

Groupe Hospitalier du Havre – Hôpital Jacques Monod

55 B Rue Gustave Flaubert, Montivilliers, 76600, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study comparing tadalafil with ambrisentan versus tadalafil alone in newly diagnosed patients with pulmonary arterial hypertension who have cardiovascular conditions

    Recruiting

    3 1 1
    Investigated Diseases:
    • Pulmonary arterial hypertension
    Investigated Drugs:
    • Ambrisentan
    • Tadalafil
    France

  • Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Elranatamab
    • Bortezomib
    • Daratumumab
    Belgium France

  • Study on Rituximab for Patients with Rheumatoid Arthritis: Comparing 200 mg and 1g Doses for Maintenance Treatment

    Recruiting

    3 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Rituximab
    • Sodium Chloride Ph. Eur.
    • Sodium Hydrogen Carbonate Pheur
    France

  • Study on the Safety and Effectiveness of Short Dual Antiplatelet Therapy with Ticagrelor, Clopidogrel, and Prasugrel in Patients Aged 65+ with Coronary Artery Disease

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Clopidogrel
    • D,L-Lysine Acetylsalicylate
    • Prasugrel
    France

  • Study on Dexamethasone for Patients with Advanced Relapsed or Refractory Multiple Myeloma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Dexamethasone
    France

  • Study on Stopping Omalizumab in Patients with Well-Controlled Severe Allergic Asthma After 3 Years of Treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Omalizumab
    France

  • Study on the Effect of Domperidone on Blood Sugar Control in Type 1 Diabetes Patients with Delayed Stomach Emptying

    Recruiting

    3 1 1
    Investigated Diseases:
    • Type 1 diabetes mellitus
    Investigated Drugs:
    • Domperidone
    France

  • Study on Colchicine and Ticagrelor for Preventing Ischemic Stroke in Patients with Atherosclerosis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ischaemic stroke
    Investigated Drugs:
    • Colchicine
    France

  • Study on Amikacin for Treating Mycobacterium Xenopi Lung Infection in Patients Using Amikacin and Drug Combination

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Amikacin
    • Ethambutol Hydrochloride
    • Rifampicin
    France

  • Study Comparing Methotrexate or Leflunomide with Targeted Therapy vs. Methotrexate or Leflunomide with Drug Combination for Rheumatoid Arthritis Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Sarilumab
    • Baricitinib
    • Filgotinib
    France
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!